TRAX Overview

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The Company's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.

Wall Street analysts forecast TRAX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

First Tracks Biotherapeutics Inc revenue for the last quarter amounts to -52.81M USD, decreased

First Tracks Biotherapeutics Inc. EPS for the last quarter amounts to -32578000.00 USD, decreased

First Tracks Biotherapeutics Inc (TRAX) has 104 emplpoyees as of June 21 2026.

Today TRAX has the market capitalization of 607.83M USD.